×

Error message

  • Failed to authorize with Brightcove
  • Failed to authorize with Brightcove
  • Failed to authorize with Brightcove
  • Failed to authorize with Brightcove
  • Failed to authorize with Brightcove
News | May 11, 2009

PET/CT Bone Imaging Trial Enrolls First 10 Patients

May 11, 2009 - The Academy of Molecular Imaging (AMI) is pleased to announce that its randomized, multicenter trial investigating the use of 18F-sodium fluoride PET/CT (18F-NaF) to detect bony metastases has enrolled its first 10 patients. This study compares conventional planar 99mTc-MDP bone imaging with 18F-NaF PET/CT in patients with breast, prostate and non-small cell lung cancers.

The protocol was developed in conjunction with the FDA and CMS, and calls for data on more than five hundred patients. The University of California-Los Angeles Medical Center, the VA Greater Los Angeles Healthcare Systems and Scottsdale Medical Imaging have all begun imaging patients.

“This exciting development is the culmination of many months’ work and an extraordinary level of collaboration,” reported Johannes Czernin, M.D., the principal investigator for the study. “While AMI is the IND holder, this important research is a result of cooperative efforts between 13 clinical sites, AMI and the molecular imaging industry. Siemens/PETNET Solutions furnished these initial 18F-NaF doses and GE Healthcare and IBA Molecular will also provide doses in the future.”

Cancer patients undergo more than 2 million planar 99mTc-MDP scans each year to determine whether the cancer has spread to their bones. 18F-NaF PET/CT bone scanning may have advantages over this conventional method because it is able to find smaller metastases and differentiate more accurately between cancerous and non-cancerous conditions.

“Cancer patients may receive better and more timely treatment if we are able to improve our ability to detect the spread of their disease earlier and more accurately,” said Ed Coleman, M.D., of Duke University Medical Center, which along with St. Louis University Hospital expects to begin enrolling participants soon. “This clinical trial is an example of the PET imaging community’s commitment to improve treatment and patient outcomes using scientifically rigorous research methods and analyses.”

Eight other sites are expected to participate upon IRB approval: Dartmouth-Hitchcock Medical Center, Stanford University Medical Center, Cedars-Sinai Medical Center, Washington University Medical Center, University of Utah Health Sciences Center, Memorial Sloan-Kettering Cancer Center, MD Anderson Cancer Center and the University of Zurich.

For more information: www.ami-imaging.org

Related Content

FDA Clears New Imaging Functionalities for Biograph mCT PET/CT Systems
Technology | PET-CT | June 21, 2018
Siemens Healthineers will announce U.S. Food and Drug Administration (FDA) clearance of four new system features for...
PET/CT Changes Care for 59 Percent of Suspected Recurrent Prostate Cancer Cases
News | Prostate Cancer | June 13, 2018
A recently presented investigational clinical trial evaluated the impact of 18F fluciclovine positron emission...
Nuclear imaging scan showing very good tissue delineation. Scan performed on a Biograph Vision positron emission tomography/computed tomography (PET-CT) system from Siemens Healthineers.

Nuclear imaging scan showing very good tissue delineation. It offers crisp overall image quality and sharply delineates the muscle and fat planes, vertebral margins and end plates, billiary radicals, renal calyces, aortic wall and papillary muscles of the heart. Scan performed on a Biograph Vision positron emission tomography/computed tomography (PET-CT) system from Siemens Healthineers.

Technology | PET-CT | June 05, 2018
June 5, 2018 — The U.S.
News | Computed Tomography (CT) | May 21, 2018
The Istituto Oncologico Veneto (IOV) in Padua, Italy, has acquired MILabs’ latest-generation Versatile Emission...
News | Radiopharmaceuticals and Tracers | May 09, 2018
Blue Earth Diagnostics signed an exclusive, worldwide agreement with Scintomics GmbH, Germany, a specialist in...
In scans of a 62-yr-old man with Gleason 4+3 PCa treated with radical prostatectomy, with rising PSA level (1.32) and PSA doubling time of 3.7 months, 64CuCl2-PET/CT images revealed 2 positive small left iliac lymph nodes (A,C), whereas 18F-Choline PET/CT (B,D) was negative (arrows).

In scans of a 62-yr-old man with Gleason 4+3 PCa treated with radical prostatectomy, with rising PSA level (1.32) and PSA doubling time of 3.7 months, 64CuCl2-PET/CT images revealed 2 positive small left iliac lymph nodes (A,C), whereas 18F-Choline PET/CT (B,D) was negative (arrows). Image courtesy of A Piccardo et al., Galliera Hospital, Genoa, Italy.

News | Prostate Cancer | March 07, 2018
An Italian study featured in the March i
Axumin PET Agent Added to NCCN Guidelines for Suspected Recurrent Prostate Cancer
News | PET Imaging | February 21, 2018
Blue Earth Diagnostics announced that Axumin (fluciclovine F 18) injection has been added to the National Comprehensive...
PSMA PET-CT Clearly Differentiates Prostate Cancer from Benign Tissue

68Ga-PSMA PET/CT images showing multifocal PCA in peripheral zone with GS of 5 1 5 5 10. (A and C) Axial PET images. (B and D) Fused PET/CT images. SUVmax of lesion in B was 84.3 and that of lesion in D was 5.7. IRS was 3, and 80% of cells were stained. Credit: Senior author V Prasad, Charité Universitätsmedizin Berlin, Berlin, Germany.

News | PET-CT | February 05, 2018
February 5, 2018 — Using nuclear medicine...
Novel PET Tracer Clearly Identifies and Tracks Bacterial Lung Infection

Representative PET/CT images of 18F-FDS and 18F-FDG in inflamed mice. Mice were inoculated with dead K. pneumoniae (10^8 CFU/mL). Imaging was performed for days 1, 2, 3 and 4 using 18F-FDG and 18F-FDS. CT images showed clear inflammation on day 2 and day 3 with corresponding high 18F-FDG uptake on PET. No significant uptake of 18F-FDS was detected for any of those 4 days. Credit: J Li et al., University of Louisville School of Medicine, Louisville, Ky.

News | PET-CT | January 22, 2018
January 22, 2018 — Researchers at the University of Louisville, Kentucky, have demonstrated that a new...
SNMMI Publishes New FDG PET/CT Appropriate Use Criteria
News | PET-CT | October 25, 2017
The Society of Nuclear Medicine and Molecular Imaging (SNMMI) has published appropriate use criteria (AUC) for FDG PET/...
Overlay Init